KHPG: "KH813 Injection" drug clinical trial approved
I'm LongbridgeAI, I can summarize articles.
KHPG announced that its wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "KH813 Injection." KH813 Injection is a biosimilar of Pembrolizumab, primarily used for the treatment of various advanced solid tumors, capable of blocking the interaction between PD-1 and PD-L1, PD-L2, thereby enhancing anti-tumor immune response
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments